ARGX · Argenx SE · Documents
$869.72
+44.11 (+5.34%)
At close · Oct 20
Return incl. dividend (before tax)
Market Cap
$55.35B
Shares
62.89M
Volume · Oct 20
535.45K
Avg daily vol (3M)
334.69K
The company's filings as submitted to the SEC's EDGAR system — 10-K, 10-Q, 8-K, proxy statements and more — listed most recent first.
| Type | AI summary | Filing Date | Period | Open |
|---|---|---|---|---|
| 6-K | argenx SE announced Phase 3 ALKIVIA results showing efgartigimod provided clinically meaningful improvements in autoimmune myositis, meeting its primary endpoint by a 15.4-point greater TIS improvement over placebo at Week 52. | 2026-10-19 | — | |
| 6-K | — | 2026-10-08 | — | |
| 6-K | — | 2026-09-29 | — | |
| Investor Event Transcript | — | 2026-09-14 | 2026-09-30 | |
| Investor Event Transcript | — | 2026-09-08 | 2026-09-30 | |
| Investor Event Transcript | — | 2026-09-01 | 2026-09-30 | |
| Investor Event Transcript | — | 2026-09-01 | 2026-09-30 | |
| 6-K | — | 2026-08-27 | — | |
| SC TO-T/A | — | 2026-08-27 | — | |
| SC TO-T/A | — | 2026-08-19 | — | |
| 6-K | — | 2026-08-17 | — | |
| SC TO-T/A | — | 2026-08-06 | — | |
| SC TO-T | — | 2026-08-06 | — | |
| 6-K | — | 2026-08-03 | — | |
| SC TO-C | — | 2026-07-28 | — | |
| 6-K | — | 2026-07-27 | — | |
| SC TO-C | — | 2026-07-27 | — | |
| 6-K | — | 2026-07-23 | 2026-06-30 | |
| 6-K | — | 2026-06-23 | — | |
| Investor Event Transcript | — | 2026-06-09 | 2026-06-30 | |
| Investor Event Transcript | — | 2026-06-03 | 2026-06-30 | |
| 6-K | — | 2026-06-03 | — | |
| Investor Event Transcript | — | 2026-05-12 | 2026-06-30 | |
| 6-K | — | 2026-05-11 | 2026-05-08 | |
| 6-K | — | 2026-05-07 | 2026-03-31 | |
| 6-K | — | 2026-05-06 | — | |
| 6-K | — | 2026-04-20 | — | |
| 6-K | — | 2026-03-20 | — | |
| 20-F | — | 2026-03-19 | 2025-12-31 | |
| 6-K | — | 2026-03-19 | 2025-12-31 | |
| 6-K | — | 2026-03-06 | — | |
| 6-K | — | 2026-02-26 | 2025-12-31 | |
| 6-K | — | 2026-02-26 | — | |
| 6-K | — | 2026-01-13 | — | |
| 6-K | — | 2026-01-12 | — | |
| 6-K | — | 2026-01-05 | — | |
| 6-K | — | 2025-12-15 | — | |
| 6-K | — | 2025-11-18 | — | |
| 6-K | — | 2025-10-30 | 2025-09-30 | |
| 6-K | — | 2025-10-29 | — | |
| 6-K | — | 2025-10-15 | — | |
| 6-K | — | 2025-10-03 | — | |
| 6-K | — | 2025-08-25 | — | |
| 6-K | — | 2025-07-31 | 2025-06-30 | |
| 6-K | — | 2025-06-30 | — | |
| 6-K | — | 2025-06-20 | — | |
| 6-K | — | 2025-06-11 | — | |
| 6-K | — | 2025-05-28 | — | |
| 6-K | — | 2025-05-08 | 2025-03-31 | |
| 6-K | — | 2025-04-28 | — |
Showing 1–50 of 149 filings
Key facts
CIK
1697862
CUSIP
04016X101
13F (30d)
58 filings
56 filers
Visit website
Investor relations